Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Therapeutics PLC

23.62
-0.4900-2.03%
Post-market: 23.50-0.1200-0.51%19:58 EDT
Volume:4.23M
Turnover:100.60M
Market Cap:17.42B
PE:-76.19
High:24.54
Open:23.70
Low:23.20
Close:24.11
Loading ...

BUZZ-Summit Therapeutics rises on clinical trial collaboration with Pfizer

Reuters
·
24 Feb

Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise -- Shares Up Pre-Bell

MT Newswires Live
·
24 Feb

Summit Therapeutics Shares up 10.2% Premarket After Collaboration With Pfizer for Cancer Drug Trial

THOMSON REUTERS
·
24 Feb

Stock Track | Summit Therapeutics Soars 6.69% Pre-market on Clinical Trial Collaboration with Pfizer

Stock Track
·
24 Feb

Earnings Flash (SMMT) Summit Therapeutics Posts Q4 Total Operating Expenses of $65.8M

MT Newswires Live
·
24 Feb

Summit Therapeutics Q4 2024 Adj EPS $(0.07) Beats $(0.08) Estimate

Benzinga
·
24 Feb

BRIEF-Summit Therapeutics Q4 Net Income USD -61.2 Million

Reuters
·
24 Feb

Summit Therapeutics Q4 Net Income USD -61.2 Million

THOMSON REUTERS
·
24 Feb

Summit Therapeutics Q4 Operating Expenses USD 65.8 Million

THOMSON REUTERS
·
24 Feb

Summit Therapeutics Q4 Operating Income USD -65.6 Million

THOMSON REUTERS
·
24 Feb

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Business Wire
·
24 Feb

Summit Therapeutics Inc - Clinical Trials Expected to Start Mid-Year

THOMSON REUTERS
·
24 Feb

Summit Therapeutics Announces Clinical Trial Collaboration With Pfizer to Evaluate Ivonescimab in Combination With Pfizer Antibody Drug Conjugates (Adcs)

THOMSON REUTERS
·
24 Feb

Summit Therapeutics - Under Terms of Agreement, Co to Provide Ivonescimab, Pfizer to Conduct Study Operations

THOMSON REUTERS
·
24 Feb

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Business Wire
·
24 Feb

Insider Stock Buying Reaches US$78.8m On Summit Therapeutics

Simply Wall St.
·
23 Feb

Press Release: Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Dow Jones
·
18 Feb

Summit Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
14 Feb

Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey
·
08 Feb

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb